19 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
26710088	248	Recent Progress in Histone Demethylase Inhibitors.	University of Oxford
26771107	113	Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives.	Glaxosmithkline
26741168	239	8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors.	The Institute of Cancer Research
26771203	114	Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives.	Glaxosmithkline
22724510	84	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.	University of Oxford
30343192	10	Lysine demethylase 5B (KDM5B): A potential anti-cancer drug target.	Zhengzhou University
27499454	22	Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors.	Genentech
27476424	56	Identification of potent, selective KDM5 inhibitors.	Constellation Pharmaceuticals
27406798	92	Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies.	Genentech
30745098	24	Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy.	Kyoto Prefectural University of Medicine
31158747	257	C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays.	Institute of Cancer Research
26682034	229	Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor.	University of Oxford
24325601	74	Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.	Sapienza University of Rome
28512031	65	From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.	Genentech
28160945	12	In search of new a-glucosidase inhibitors: Imidazolylpyrazole derivatives.	University of The Punjab